Harmony Biosciences Holdings Inc (HRMY)

Sep 3, 2026, 8:05 AM EDT - 5 days ago

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Aug 27, 2026, 8:05 AM EDT - 12 days ago

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

2026-08-26T11:15:43.000Z - 13 days ago

Harmony Biosciences initiated with an Outperform at Wolfe Research

Aug 13, 2026, 1:30 PM EDT - 26 days ago

Harmony Biosciences Holdings Transcript: Piper Sandler Virtual CNS Symposium

Aug 6, 2026, 8:05 AM EDT - 4 weeks ago

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

2026-08-05T14:07:22.000Z - 4 weeks ago

Harmony Biosciences price target raised to $34 from $29 at Truist

2026-08-05T13:49:15.000Z - 4 weeks ago

Harmony Biosciences price target raised to $39 from $36 at Deutsche Bank

2026-08-05T11:33:52.000Z - 4 weeks ago

Harmony Biosciences price target raised to $37 from $33 at UBS

2026-08-05T10:32:17.000Z - 4 weeks ago

Harmony Biosciences price target raised to $30 from $28 at BofA

Aug 4, 2026, 8:30 AM EDT - 5 weeks ago

Harmony Biosciences Holdings Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 5 weeks ago

Harmony Biosciences Holdings Earnings release: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 5 weeks ago

Harmony Biosciences Holdings Slides: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 5 weeks ago

Harmony Biosciences Holdings Quarterly report: Q2 2026

Aug 4, 2026, 7:30 AM EDT - 5 weeks ago

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

2026-08-03T11:25:10.000Z - 5 weeks ago

Harmony Biosciences price target raised to $51 from $50 at Mizuho

2026-07-31T11:32:45.000Z - 5 weeks ago

Harmony Biosciences price target raised to $51 from $50 at Mizuho

Jul 21, 2026, 8:05 AM EDT - 7 weeks ago

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Jul 16, 2026, 8:30 AM EDT - 7 weeks ago

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

2026-06-30T13:40:54.000Z - 2 months ago

Harmony Biosciences price target raised to $36 from $30 at Deutsche Bank

Jun 15, 2026, 10:53 AM EDT - 2 months ago

20 growth stocks priced as value stocks

ADMA AMG ANIP ARR BILL CG DAN

Jun 11, 2026, 8:05 AM EDT - 2 months ago

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Jun 9, 2026, 8:40 AM EDT - 3 months ago

Harmony Biosciences Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 27, 2026, 8:05 AM EDT - 3 months ago

Harmony Biosciences to Participate in Upcoming Investor Conferences

May 14, 2026, 4:00 PM EDT - 3 months ago

Harmony Biosciences Holdings Transcript: AGM 2026

2026-05-08T14:41:09.000Z - 4 months ago

Harmony Biosciences price target raised to $29 from $25 at Truist

2026-05-07T14:35:42.000Z - 4 months ago

Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B

May 7, 2026, 8:30 AM EDT - 4 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Harmony Biosciences Holdings Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Harmony Biosciences Holdings Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Harmony Biosciences Holdings Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 4 months ago

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Apr 23, 2026, 8:05 AM EDT - 4 months ago

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-22T15:04:39.000Z - 4 months ago

Harmony Biosciences price target raised to $72 from $62 at Oppenheimer

2026-04-21T16:53:45.000Z - 4 months ago

Harmony patent litigation update ‘major positive,’ says Mizuho

Apr 16, 2026, 8:05 AM EDT - 4 months ago

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Apr 14, 2026, 8:05 AM EDT - 4 months ago

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Apr 13, 2026, 9:30 AM EDT - 4 months ago

Harmony Biosciences Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 3, 2026, 8:00 AM EDT - 5 months ago

Harmony Biosciences Holdings Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 5 months ago

Harmony Biosciences Holdings Proxy statement: Proxy filing

Apr 2, 2026, 8:05 AM EDT - 5 months ago

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Mar 31, 2026, 8:05 AM EDT - 5 months ago

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

Feb 24, 2026, 8:30 AM EST - 6 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Harmony Biosciences Holdings Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Harmony Biosciences Holdings Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Harmony Biosciences Holdings Slides: Q4 2025

Feb 24, 2026, 7:30 AM EST - 6 months ago

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Feb 17, 2026, 8:05 AM EST - 6 months ago

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Feb 10, 2026, 8:05 AM EST - 7 months ago

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 13, 2026, 7:30 PM EST - 7 months ago

Harmony Biosciences Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 7 months ago

Harmony Biosciences Holdings Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:05 AM EST - 7 months ago

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Jan 7, 2026, 8:05 AM EST - 8 months ago

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 6:30 AM EST - 8 months ago

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Dec 8, 2025, 8:05 AM EST - 9 months ago

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Dec 3, 2025, 10:30 AM EST - 9 months ago

Harmony Biosciences Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 2:35 PM EST - 9 months ago

Harmony Biosciences Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:05 AM EST - 9 months ago

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Nov 24, 2025, 8:05 AM EST - 9 months ago

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Nov 19, 2025, 8:05 AM EST - 9 months ago

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Nov 4, 2025, 8:30 AM EST - 10 months ago

Harmony Biosciences Holdings Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Harmony Biosciences Holdings Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Harmony Biosciences Holdings Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Harmony Biosciences Holdings Slides: Q3 2025

Nov 4, 2025, 7:30 AM EST - 10 months ago

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Oct 23, 2025, 8:05 AM EDT - 10 months ago

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Sep 24, 2025, 8:33 AM EDT - 11 months ago

Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

Sep 24, 2025, 8:00 AM EDT - 11 months ago

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Sep 15, 2025, 2:18 PM EDT - 11 months ago

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

AGYS ASTH CORT ENVA GSHD HASI KNTK

Sep 4, 2025, 2:10 PM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Aug 21, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Quarterly report: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Earnings release: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Slides: Q2 2025

Aug 5, 2025, 7:30 AM EDT - 1 year ago

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

Jul 22, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 17, 2025, 10:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: H.C. Wainwright "HCW@Home" Series

Jul 15, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Jun 11, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Jun 9, 2025, 3:20 PM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Jun 4, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Harmony Biosciences Holdings Slides: Q1 2025

May 6, 2025, 7:30 AM EDT - 1 year ago

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

May 6, 2025, 7:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Slides: Corporate Presentation

Apr 29, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Apr 9, 2025, 3:00 PM EDT - 1 year ago

Harmony Biosciences Holdings Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Harmony Biosciences Holdings Proxy statement: Proxy Filing

Apr 3, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors